MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy.
Year: 2022
Type: article
Abstract: alterations may benefit from combinations of targeted inhibitors of MDM2/4 and CDK4/6, as well as immunotherapy.
Source: PubMed
Authors: Taylor E Arnoff, Wafik S El-Deiry
Institutions: Brown University, Lifespan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4285744152